Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2020 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Theranostics. 2020 Feb 3;10(6):2645-2658. doi: 10.7150/thno.38533. eCollection 2020.
Theranostics. 2020.
PMID: 32194826
Free PMC article.
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
Hambach J, Riecken K, Cichutek S, Schütze K, Albrecht B, Petry K, Röckendorf JL, Baum N, Kröger N, Hansen T, Schuch G, Haag F, Adam G, Fehse B, Bannas P, Koch-Nolte F.
Hambach J, et al. Among authors: petry k.
Cells. 2020 Jan 29;9(2):321. doi: 10.3390/cells9020321.
Cells. 2020.
PMID: 32013131
Free PMC article.
Item in Clipboard
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K, Petry K, Hambach J, Schuster N, Fumey W, Schriewer L, Röckendorf J, Menzel S, Albrecht B, Haag F, Stortelers C, Bannas P, Koch-Nolte F.
Schütze K, et al. Among authors: petry k.
Front Immunol. 2018 Nov 19;9:2553. doi: 10.3389/fimmu.2018.02553. eCollection 2018.
Front Immunol. 2018.
PMID: 30524421
Free PMC article.
Item in Clipboard
Cite
Cite